A study published in Engineering has demonstrated that the N-glycome of serum-derived extracellular vesicles (EVs) can serve as a non-invasive biosignature for the diagnosis and classification of childhood epilepsy, offering a new tool for precision and longitudinal monitoring in clinical settings.